JP2013513610A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013513610A5 JP2013513610A5 JP2012543222A JP2012543222A JP2013513610A5 JP 2013513610 A5 JP2013513610 A5 JP 2013513610A5 JP 2012543222 A JP2012543222 A JP 2012543222A JP 2012543222 A JP2012543222 A JP 2012543222A JP 2013513610 A5 JP2013513610 A5 JP 2013513610A5
- Authority
- JP
- Japan
- Prior art keywords
- photodynamic therapy
- nanoparticles
- photosensitizer
- diseases
- pharmaceutical formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002105 nanoparticle Substances 0.000 claims 10
- 238000002428 photodynamic therapy Methods 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 239000003504 photosensitizing agent Substances 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
- 239000007864 aqueous solution Substances 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 3
- 239000003381 stabilizer Substances 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000003960 organic solvent Substances 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 230000000087 stabilizing effect Effects 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- HORNXRXVQWOLPJ-UHFFFAOYSA-N 3-chlorophenol Chemical compound OC1=CC=CC(Cl)=C1 HORNXRXVQWOLPJ-UHFFFAOYSA-N 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- LYPFDBRUNKHDGX-SOGSVHMOSA-N N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 Chemical group N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 LYPFDBRUNKHDGX-SOGSVHMOSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108010038807 Oligopeptides Proteins 0.000 claims 1
- 102000015636 Oligopeptides Human genes 0.000 claims 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- 208000012931 Urologic disease Diseases 0.000 claims 1
- 230000000274 adsorptive effect Effects 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- 150000004036 bacteriochlorins Chemical class 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 125000000837 carbohydrate group Chemical group 0.000 claims 1
- SURLGNKAQXKNSP-DBLYXWCISA-N chlorin Chemical compound C\1=C/2\N/C(=C\C3=N/C(=C\C=4NC(/C=C\5/C=CC/1=N/5)=CC=4)/C=C3)/CC\2 SURLGNKAQXKNSP-DBLYXWCISA-N 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 238000007710 freezing Methods 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 125000003827 glycol group Chemical group 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000007908 nanoemulsion Substances 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 229960000502 poloxamer Drugs 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229950008882 polysorbate Drugs 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 150000004032 porphyrins Chemical class 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 229960002197 temoporfin Drugs 0.000 claims 1
- 208000014001 urinary system disease Diseases 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28589509P | 2009-12-11 | 2009-12-11 | |
| US61/285,895 | 2009-12-11 | ||
| US12/941,447 US20110275686A1 (en) | 2009-12-11 | 2010-11-08 | Nanoparticle carrier systems based on poly(dl-lactic-co-glycolic acid) (plga) for photodynamic therapy (pdt) |
| US12/941,447 | 2010-11-08 | ||
| PCT/US2010/059367 WO2011071970A2 (en) | 2009-12-11 | 2010-12-08 | Nanoparticle carrier systems based on poly(dl-lactic-co-glycolic acid) (plga) for photodynamic therapy (pdt) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013513610A JP2013513610A (ja) | 2013-04-22 |
| JP2013513610A5 true JP2013513610A5 (https=) | 2014-08-14 |
| JP5868869B2 JP5868869B2 (ja) | 2016-02-24 |
Family
ID=44146154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012543222A Expired - Fee Related JP5868869B2 (ja) | 2009-12-11 | 2010-12-08 | 光力学的療法のための乳酸・グリコール酸共重合体をベースにしたナノ粒子キャリアシステム |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20110275686A1 (https=) |
| EP (1) | EP2509633B1 (https=) |
| JP (1) | JP5868869B2 (https=) |
| CN (2) | CN102740892A (https=) |
| BR (1) | BR112012013951A2 (https=) |
| CA (1) | CA2784005C (https=) |
| WO (1) | WO2011071970A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9211283B2 (en) * | 2009-12-11 | 2015-12-15 | Biolitec Pharma Marketing Ltd | Nanoparticle carrier systems based on human serum albumin for photodynamic therapy |
| GB0922066D0 (en) | 2009-12-17 | 2010-02-03 | Univ Belfast | Modulator |
| WO2013012628A2 (en) * | 2011-07-15 | 2013-01-24 | The University Of Georgia Research Foundation, Inc. | Immune-stimulating photoactive hybrid nanoparticles |
| JP2013094135A (ja) * | 2011-11-02 | 2013-05-20 | Waseda Univ | 人工ナノ材料の安全性を評価する方法 |
| CN103169968B (zh) * | 2013-03-12 | 2014-11-26 | 中国科学院理化技术研究所 | 一种基于白蛋白的疏水二氢卟吩光敏剂纳米药物制剂、制备方法及其应用 |
| WO2015040622A1 (en) * | 2013-09-22 | 2015-03-26 | Laster Brenda | The continuous long-term controlled release of telomerase inhibitors |
| CN103933568B (zh) * | 2014-05-12 | 2016-03-30 | 南京师范大学 | 一种水溶性竹红菌素plga纳米粒及其制备方法 |
| EP3201201B1 (en) | 2014-09-30 | 2022-01-26 | biolitec unternehmensbeteiligungs II AG | Specifically meso-substituted porphyrins and chlorins for photodynamic therapy |
| CN106620893B (zh) | 2015-07-23 | 2021-07-30 | 爱博诺德(北京)医疗科技股份有限公司 | 用于眼部疾病光治疗的材料 |
| US10786465B2 (en) | 2015-07-27 | 2020-09-29 | The Texas A&M University System | Polymer/copolymer nanoparticles conjugated to gambogic acid |
| CN105343878B (zh) * | 2015-11-30 | 2018-10-19 | 中国人民解放军第三军医大学第三附属医院 | 还原敏感型水溶性分子靶向光敏剂及其制备方法和应用 |
| ES3011714T3 (en) | 2016-02-26 | 2025-04-08 | Biolitec Holding Gmbh & Co Kg | Conjugates of porphyrinoid photosensitizers and glycerol-based polymers for photodynamic therapy |
| CN109481418B (zh) * | 2017-12-19 | 2022-08-19 | 深圳先进技术研究院 | 抗肿瘤纳米颗粒及其制备方法和应用 |
| EP3626268A1 (en) | 2018-09-24 | 2020-03-25 | Westfälische Wilhelms-Universität Münster | Polymer-particle light-cleavable carrier systems for photodynamic therapy |
| WO2020120474A1 (en) | 2018-12-10 | 2020-06-18 | Universität Hamburg | Specifically glyco-substituted porphyrins and chlorins for photodynamic therapy |
| CN113543810B (zh) * | 2019-03-08 | 2024-02-09 | 北卡罗莱纳州立大学 | 光热疗法促进cart t细胞的肿瘤浸润和抗肿瘤活性 |
| CN111000804B (zh) * | 2019-12-05 | 2022-02-11 | 东南大学 | 一种甘露糖靶向的热响应铂纳米颗粒及其制备方法和应用 |
| CA3213957A1 (en) * | 2021-04-07 | 2022-10-13 | Jonathan S. Lindsey | Porphyrin-hydroporphyrin compounds, compositions comprising the same and methods of use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3372558B2 (ja) * | 1990-09-14 | 2003-02-04 | 中外製薬株式会社 | マイクロカプセル型徐放性製剤及びその製造法 |
| CA2229285A1 (en) | 1995-09-21 | 1997-03-27 | Robert Gurny | Nanoparticles in photodynamic therapy |
| JP3765338B2 (ja) * | 1995-12-15 | 2006-04-12 | 武田薬品工業株式会社 | 注射用徐放性製剤の製造法 |
| US5829448A (en) * | 1996-10-30 | 1998-11-03 | Photogen, Inc. | Method for improved selectivity in photo-activation of molecular agents |
| GB0001455D0 (en) * | 2000-01-21 | 2000-03-15 | Scotia Holdings Plc | Porphyrins and related compounds |
| US20060083778A1 (en) * | 2002-05-03 | 2006-04-20 | Dean Allison | Controlled release compositions of estradiol metabolites |
| US7455858B2 (en) | 2002-05-16 | 2008-11-25 | Qlt Inc. | Compositions and methods for delivery of photosensitive drugs |
| EP1583473A2 (en) | 2003-01-16 | 2005-10-12 | St. Johns University New York | Nanoparticle based stabilization of ir fluorescent dyes |
| US20050048109A1 (en) * | 2003-08-26 | 2005-03-03 | Ceramoptec Industries, Inc. | Non-polar photosensitizer formulations for photodynamic therapy |
| WO2006133271A2 (en) * | 2005-06-06 | 2006-12-14 | The General Hospital Corporation | Compositions and methods relating to target-specific photodynamic therapy |
-
2010
- 2010-11-08 US US12/941,447 patent/US20110275686A1/en not_active Abandoned
- 2010-12-08 JP JP2012543222A patent/JP5868869B2/ja not_active Expired - Fee Related
- 2010-12-08 CA CA2784005A patent/CA2784005C/en not_active Expired - Fee Related
- 2010-12-08 BR BR112012013951A patent/BR112012013951A2/pt not_active IP Right Cessation
- 2010-12-08 WO PCT/US2010/059367 patent/WO2011071970A2/en not_active Ceased
- 2010-12-08 CN CN2010800629259A patent/CN102740892A/zh active Pending
- 2010-12-08 CN CN201710128404.2A patent/CN106913533A/zh active Pending
- 2010-12-08 EP EP10836583.4A patent/EP2509633B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013513610A5 (https=) | ||
| JP2013513609A5 (https=) | ||
| Zhu et al. | Pillararene-based supramolecular systems for theranostics and bioapplications | |
| Nair et al. | Advanced drug delivery and therapeutic strategies for tuberculosis treatment | |
| JP5868869B2 (ja) | 光力学的療法のための乳酸・グリコール酸共重合体をベースにしたナノ粒子キャリアシステム | |
| Zhang et al. | Carrier-free, chemophotodynamic dual nanodrugs via self-assembly for synergistic antitumor therapy | |
| CN103030140B (zh) | 透明质酸修饰的氧化石墨烯及其药物组合物的制备方法与应用 | |
| JP5972171B2 (ja) | 光力学的療法のためのヒト血清アルブミンをベースにしたナノ粒子キャリアシステム | |
| Zheng et al. | Macrocyclic amphiphiles for drug delivery | |
| Bao et al. | Nanoscale metal–organic framework composites for phototherapy and synergistic therapy of cancer | |
| ES2385995B2 (es) | Nanocápsulas con cubierta polimérica | |
| Shi et al. | Nano-formulations in disease therapy: designs, advances, challenges, and future directions | |
| KR102640250B1 (ko) | 암 및 안 질환의 치료를 위한 알부민 나노입자들 | |
| JP2007500712A (ja) | カプセル化および徐放のための組成物 | |
| JP2015519330A5 (https=) | ||
| CN110665003A (zh) | 一种双载药无载体纳米粒及其制备方法 | |
| CN109678905A (zh) | 一种配位驱动的自组装超分子笼、制备方法及其应用 | |
| CN109381428A (zh) | 用于肿瘤光动力治疗联合免疫治疗的纳米制剂 | |
| Jug et al. | Revisiting niclosamide formulation approaches–a pathway toward drug repositioning | |
| CN106913882B (zh) | 一种聚乙二醇-藤黄酸脂质体和制备方法及其在治疗恶性肿瘤中的应用 | |
| Jiang et al. | New insights into nanosystems for non-small-cell lung cancer: diagnosis and treatment | |
| Luan et al. | Mannosamine-engineered nanoparticles for precision rifapentine delivery to macrophages: Advancing targeted therapy against Mycobacterium tuberculosis | |
| Esfahani et al. | Functionalized and theranostic lipidic and tocosomal drug delivery systems: potentials and limitations in cancer photodynamic therapy | |
| CN104274401A (zh) | 一种基于hcpt-peg的喜树碱类药物的高载药纳米混悬剂及其制备方法 | |
| CN109481696A (zh) | 用于癌症光动力治疗和化学治疗的药物及其制备方法 |